Business
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period. Net revenues for the full year 2024 were $38 million.
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"2024 highlights include expanded product labeling, key FDA designations and new study publications","length":98,"tagName":"p","attribs":{}},{"type":"text","content":"Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval","length":93,"tagName":"p","attribs":{}},{"type":"text","content":"NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period. Net revenues for the full year 2024 were $38 million.","length":381,"tagName":"p"},{"type":"image","alt":"Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.)","displaySize":"","headline":null,"caption":"Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":85,"url":"https://media.zenfs.com/en/prnewswire.com/3afebe83ec3d4bc266a4bcc9278af913"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W65H8Am_Z_mSA2sDK0ostg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3afebe83ec3d4bc266a4bcc9278af913","width":400,"height":85}},"href":"https://mma.prnewswire.com/media/84325/Cumberland_Pharmaceuticals_logo_new1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Cumberland ended the year with $76 million in total assets – including $18 million in cash, $53 million in liabilities and $23 million of shareholders' equity.","length":163,"tagName":"p"},{"type":"text","content":""2024 was a transformative year for our Company, marked by expanded product labeling, key FDA designations and significant new study publications that underscore our commitment to improving patient care," said Cumberland Pharmaceuticals CEO A.J. Kazimi. "As we move into 2025, we remain focused on driving growth, delivering value to our stakeholders and advancing our mission."","length":398,"tagName":"p"},{"type":"text","content":"Cumberland started 2025 with several significant developments, including:","length":73,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cumberland recently ann...